NO2825156T3 - - Google Patents
Info
- Publication number
- NO2825156T3 NO2825156T3 NO13710293A NO13710293A NO2825156T3 NO 2825156 T3 NO2825156 T3 NO 2825156T3 NO 13710293 A NO13710293 A NO 13710293A NO 13710293 A NO13710293 A NO 13710293A NO 2825156 T3 NO2825156 T3 NO 2825156T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001803 | 2012-03-16 | ||
EP13710293.5A EP2825156B1 (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
PCT/EP2013/000698 WO2013135359A1 (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2825156T3 true NO2825156T3 (da) | 2017-12-23 |
Family
ID=47901004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO13710293A NO2825156T3 (da) | 2012-03-16 | 2013-03-11 |
Country Status (21)
Country | Link |
---|---|
US (2) | US9878044B2 (da) |
EP (1) | EP2825156B1 (da) |
JP (2) | JP6527331B2 (da) |
KR (2) | KR102208586B1 (da) |
CN (1) | CN104168888A (da) |
AU (2) | AU2013231638B2 (da) |
BR (1) | BR112014022451B1 (da) |
CA (1) | CA2867169C (da) |
DK (1) | DK2825156T3 (da) |
ES (1) | ES2644778T3 (da) |
HK (1) | HK1198924A1 (da) |
IL (1) | IL234550A (da) |
MX (1) | MX354811B (da) |
NO (1) | NO2825156T3 (da) |
NZ (1) | NZ631034A (da) |
PT (1) | PT2825156T (da) |
RU (1) | RU2654210C2 (da) |
SG (2) | SG10201610401XA (da) |
TW (1) | TWI586370B (da) |
WO (1) | WO2013135359A1 (da) |
ZA (1) | ZA201407490B (da) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2804472T3 (es) | 2005-12-13 | 2021-02-08 | Harvard College | Estructuras para trasplante celular |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP3620185A1 (en) | 2010-10-06 | 2020-03-11 | President and Fellows of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CN104244929B (zh) | 2012-04-16 | 2017-04-05 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
RU2021109685A (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY |
CN114099793A (zh) | 2015-04-10 | 2022-03-01 | 哈佛学院院长等 | 免疫细胞捕获装置及其制备和使用方法 |
AR105910A1 (es) * | 2015-09-04 | 2017-11-22 | Obi Pharma Inc | Matrices de glicano y método de uso |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
CN105505382B (zh) * | 2015-12-04 | 2017-06-27 | 安徽师范大学 | 一种铜纳米簇溶液的制备方法及应用 |
DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
EP3411475A4 (en) | 2016-02-06 | 2019-09-11 | President and Fellows of Harvard College | REGENERATION OF THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
TWI780045B (zh) | 2016-03-29 | 2022-10-11 | 台灣浩鼎生技股份有限公司 | 抗體、醫藥組合物及方法 |
TWI697333B (zh) | 2016-04-22 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法 |
JP7088911B2 (ja) | 2016-05-18 | 2022-06-21 | モデルナティエックス インコーポレイテッド | リラキシンをコードするポリヌクレオチド |
JP2019522486A (ja) * | 2016-07-13 | 2019-08-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
AU2017302038B2 (en) | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
US11643456B2 (en) | 2016-07-29 | 2023-05-09 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
CN110114461A (zh) | 2016-08-17 | 2019-08-09 | 博德研究所 | 新型crispr酶和系统 |
WO2018035387A1 (en) * | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2018038549A1 (ko) * | 2016-08-24 | 2018-03-01 | 울산대학교 산학협력단 | Dtbp를 이용한 미생물 농축 또는 핵산 추출 방법 |
US11584924B2 (en) | 2016-08-24 | 2023-02-21 | Infusion Tech | Method for concentrating microorganism or extracting nucleic acid using DTBP |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
DE17829597T1 (de) * | 2016-11-30 | 2019-12-05 | Noxxon Pharma Ag | Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz |
JP7220154B2 (ja) | 2017-03-15 | 2023-02-09 | モデルナティエックス インコーポレイテッド | アミノ脂質の結晶形態 |
HUE060693T2 (hu) | 2017-03-15 | 2023-04-28 | Modernatx Inc | Vegyület és készítmények terápiás szerek intracelluláris bejuttatására |
WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
CA3091974A1 (en) * | 2017-11-09 | 2019-05-16 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
AU2020235801A1 (en) | 2019-03-13 | 2021-11-04 | Merck Patent Gmbh | Process for the preparation of lipidated proteinaceous structures |
CA3154618A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2967069D1 (en) | 1978-01-16 | 1984-08-02 | Univ Boston | Effecting cellular uptake of molecules |
US4144034A (en) * | 1978-03-27 | 1979-03-13 | Texaco Inc. | Polyether-maleic anhydride reaction product containing motor fuel composition |
EP0142010B1 (de) | 1983-11-10 | 1987-12-23 | Hoesch Aktiengesellschaft | Verfahren und Vorrichtung zum elektrolytischen Abscheiden von Metallen |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
IT1254135B (it) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica. |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
CN1263473A (zh) | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
AU783647B2 (en) * | 1999-04-20 | 2005-11-17 | University Of British Columbia, The | Cationic peg-lipids and methods of use |
WO2001022995A1 (en) | 1999-09-30 | 2001-04-05 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
WO2002094185A2 (en) | 2001-05-18 | 2002-11-28 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
JP4678967B2 (ja) * | 2001-03-08 | 2011-04-27 | 本田技研工業株式会社 | ゲル化性有機化合物及びそれを用いるゲル |
GB0106041D0 (en) * | 2001-03-12 | 2001-05-02 | Cancer Res Ventures Ltd | Lipids and liposomes |
JP5093547B2 (ja) * | 2001-08-24 | 2012-12-12 | 日本ケミカルリサーチ株式会社 | 両イオン性脂質およびその用途 |
WO2003022910A1 (en) | 2001-09-08 | 2003-03-20 | Access Pharmaceuticals, Inc. | Synthesis and uses of polymer gel nanoparticle networks |
EP1308167A1 (de) | 2001-11-06 | 2003-05-07 | Pickl, Winfried, Ao. Univ. Prof. Dr. | Antigenpräsentierende Vesikel |
JP4331927B2 (ja) * | 2002-08-29 | 2009-09-16 | 協立化学産業株式会社 | 無機ナノ粒子−有機化合物複合体およびそれの一次元配列集積構造体 |
WO2004111192A2 (en) * | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
DE602005025659D1 (da) | 2004-09-23 | 2011-02-10 | Guerbet Sa | |
WO2007087341A2 (en) | 2006-01-25 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Tolerogenic biodegradable artificial antigen presenting system |
WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
US20090285881A1 (en) * | 2008-04-16 | 2009-11-19 | Abbott Laboratories | Cationic lipids and uses thereof |
US20100104629A1 (en) | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
RU2409587C2 (ru) * | 2009-03-04 | 2011-01-20 | Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" | 1-гексадецил-5-(1-пиренбутил)-n-(l-орнитил)-l-глутамат бисхлорид |
KR101817491B1 (ko) | 2010-09-02 | 2018-01-11 | 더 스크립스 리서치 인스티튜트 | 나노입자-기반 종양-표적 약물 전달 |
US20120294924A1 (en) * | 2011-04-29 | 2012-11-22 | Thomas Tice | Peptide-Lipid Conjugates And Uses Thereof |
HUE040256T2 (hu) * | 2012-03-16 | 2019-02-28 | Merck Patent Gmbh | Aminosav lipidek |
-
2013
- 2013-03-11 AU AU2013231638A patent/AU2013231638B2/en active Active
- 2013-03-11 ES ES13710293.5T patent/ES2644778T3/es active Active
- 2013-03-11 CN CN201380013774.1A patent/CN104168888A/zh active Pending
- 2013-03-11 NO NO13710293A patent/NO2825156T3/no unknown
- 2013-03-11 KR KR1020147028906A patent/KR102208586B1/ko active IP Right Grant
- 2013-03-11 PT PT137102935T patent/PT2825156T/pt unknown
- 2013-03-11 KR KR1020207008113A patent/KR20200036033A/ko not_active Application Discontinuation
- 2013-03-11 NZ NZ631034A patent/NZ631034A/en unknown
- 2013-03-11 DK DK13710293.5T patent/DK2825156T3/da active
- 2013-03-11 JP JP2014561310A patent/JP6527331B2/ja active Active
- 2013-03-11 SG SG10201610401XA patent/SG10201610401XA/en unknown
- 2013-03-11 EP EP13710293.5A patent/EP2825156B1/en active Active
- 2013-03-11 CA CA2867169A patent/CA2867169C/en active Active
- 2013-03-11 MX MX2014010808A patent/MX354811B/es active IP Right Grant
- 2013-03-11 US US14/384,702 patent/US9878044B2/en active Active
- 2013-03-11 BR BR112014022451-0A patent/BR112014022451B1/pt active IP Right Grant
- 2013-03-11 WO PCT/EP2013/000698 patent/WO2013135359A1/en active Application Filing
- 2013-03-11 SG SG11201405552VA patent/SG11201405552VA/en unknown
- 2013-03-11 RU RU2014141545A patent/RU2654210C2/ru active
- 2013-03-15 TW TW102109381A patent/TWI586370B/zh active
-
2014
- 2014-09-09 IL IL234550A patent/IL234550A/en active IP Right Grant
- 2014-10-15 ZA ZA2014/07490A patent/ZA201407490B/en unknown
- 2014-12-11 HK HK14112479.9A patent/HK1198924A1/xx unknown
-
2018
- 2018-01-11 US US15/867,985 patent/US11510988B2/en active Active
- 2018-01-12 AU AU2018200293A patent/AU2018200293B2/en active Active
- 2018-05-29 JP JP2018102256A patent/JP2018141015A/ja active Pending